TY  - BOOK
AU  - Bhogal, Sukhdeep
TI  - Is There a Role for Triple Therapy After ACS?. [Review]
PY  - 2022///
KW  - *Acute Coronary Syndrome
KW  - *Atrial Fibrillation
KW  - *Percutaneous Coronary Intervention
KW  - Acute Coronary Syndrome/co [Complications]
KW  - Acute Coronary Syndrome/dt [Drug Therapy]
KW  - Administration, Oral
KW  - Anticoagulants/ae [Adverse Effects]
KW  - Atrial Fibrillation/co [Complications]
KW  - Atrial Fibrillation/dt [Drug Therapy]
KW  - Drug Therapy, Combination
KW  - Fibrinolytic Agents/ae [Adverse Effects]
KW  - Humans
KW  - Platelet Aggregation Inhibitors/ae [Adverse Effects]
KW  - MedStar Washington Hospital Center
KW  - Advanced Cardiac Catheterization Research Fellowship
KW  - Journal Article
KW  - Review
N2  - PURPOSE OF REVIEW: The optimal antithrombotic strategy in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) remains the subject of controversy. In this article, we review the current evidence for the use of triple therapy in acute coronary syndrome (ACS) patients; RECENT FINDINGS: The recently published trials of AF patients undergoing PCI have shown that combination of non-vitamin K oral anticoagulants (NOACs) with an antiplatelet agent is either superior or non-inferior to vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) in reducing bleeding complications with no difference in regard to thromboembolic events. Currently, the use of dual therapy (preferably with a NOAC and clopidogrel) is recommended over triple therapy in these patients. The optimal duration should be guided by the assessment of an individual's risk of thrombosis and bleeding events. Copyright (c) 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature
UR  - https://dx.doi.org/10.1007/s11886-022-01634-3
ER  -